# Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

> **NCT01205152** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Hypophosphatasia

## Interventions

- **BIOLOGICAL:** asfotase alfa

## Key facts

- **NCT ID:** NCT01205152
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01205152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01205152, "Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01205152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*